162 related articles for article (PubMed ID: 25826681)
1. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.
Dodbiba L; Teichman J; Fleet A; Thai H; Starmans MH; Navab R; Chen Z; Girgis H; Eng L; Espin-Garcia O; Shen X; Bandarchi B; Schwock J; Tsao MS; El-Zimaity H; Der SD; Xu W; Bristow RG; Darling GE; Boutros PC; Ailles LE; Liu G
PLoS One; 2015; 10(3):e0121872. PubMed ID: 25826681
[TBL] [Abstract][Full Text] [Related]
2. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment.
Dodbiba L; Teichman J; Fleet A; Thai H; Sun B; Panchal D; Patel D; Tse A; Chen Z; Faluyi OO; Renouf DJ; Girgis H; Bandarchi B; Schwock J; Xu W; Bristow RG; Tsao MS; Darling GE; Ailles LE; El-Zimaity H; Liu G
Lab Invest; 2013 Apr; 93(4):397-407. PubMed ID: 23399854
[TBL] [Abstract][Full Text] [Related]
3. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
[TBL] [Abstract][Full Text] [Related]
4. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
John T; Kohler D; Pintilie M; Yanagawa N; Pham NA; Li M; Panchal D; Hui F; Meng F; Shepherd FA; Tsao MS
Clin Cancer Res; 2011 Jan; 17(1):134-41. PubMed ID: 21081655
[TBL] [Abstract][Full Text] [Related]
5. GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion.
Zhang W; Williams TA; Bhagwath AS; Hiermann JS; Peacock CD; Watkins DN; Ding P; Park JY; Montgomery EA; Forastiere AA; Jie C; Cantarel BL; Pham TH; Wang DH
Lab Invest; 2020 Jan; 100(1):16-26. PubMed ID: 31292541
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Santander S; Cebrián C; Esquivias P; Conde B; Esteva F; Jiménez P; Ortego J; Lanas A; Piazuelo E
Int J Oncol; 2012 Feb; 40(2):527-34. PubMed ID: 21971589
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
8. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
9. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
van Duin M; van Marion R; Vissers KJ; Hop WC; Dinjens WN; Tilanus HW; Siersema PD; van Dekken H
Cytogenet Genome Res; 2007; 118(2-4):130-7. PubMed ID: 18000363
[TBL] [Abstract][Full Text] [Related]
10. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
11. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.
Martins-Filho SN; Weiss J; Pham NA; Li Q; Cabanero M; Fares A; Stewart EL; Shi R; Patel D; Pal P; McConnell J; Bradbury PA; Sacher AG; Leighl NB; Grindlay A; Allison F; Li M; Yasufuku K; Shepherd FA; Moghal N; Tsao MS; Liu G
Lung Cancer; 2020 Jul; 145():144-151. PubMed ID: 32447118
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts.
Read M; Liu D; Duong CP; Cullinane C; Murray WK; Fennell CM; Shortt J; Westerman D; Burton P; Clemons NJ; Phillips WA
Ann Surg Oncol; 2016 Jan; 23(1):305-11. PubMed ID: 25691278
[TBL] [Abstract][Full Text] [Related]
13. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.
Wang J; Milton DR; He L; Komaki R; Liao Z; Crane CH; Minsky BD; Thall PF; Lin SH
J Thorac Oncol; 2015 Mar; 10(3):518-26. PubMed ID: 25695222
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinoma of the GEJ: gastric or oesophageal cancer?
Rüschoff J
Recent Results Cancer Res; 2012; 196():107-13. PubMed ID: 23129369
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
16. Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma.
Hassan MS; von Holzen U
Methods Mol Biol; 2018; 1756():151-164. PubMed ID: 29600368
[TBL] [Abstract][Full Text] [Related]
17. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
18. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
20. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.
Zhang T; Zhang L; Fan S; Zhang M; Fu H; Liu Y; Yin X; Chen H; Xie L; Zhang J; Gavine PR; Gu Y; Ni X; Su X
PLoS One; 2015; 10(7):e0134493. PubMed ID: 26217940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
